40 related articles for article (PubMed ID: 17038881)
21. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates.
Pullen J; de Rozario L; Stolk LM; Degraeuwe PL; van Tiel FH; Zimmermann LJ
Ther Drug Monit; 2006 Jun; 28(3):351-8. PubMed ID: 16778719
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates.
Pullen J; Stolk LM; Nieman FH; Degraeuwe PL; van Tiel FH; Zimmermann LJ
Ther Drug Monit; 2006 Apr; 28(2):226-31. PubMed ID: 16628135
[TBL] [Abstract][Full Text] [Related]
23. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation.
Asbury WH; Darsey EH; Rose WB; Murphy JE; Buffington DE; Capers CC
Ann Pharmacother; 1993 Apr; 27(4):490-6. PubMed ID: 8477127
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic parameters of vancomycin in critically ill patients.
Llopis-Salvia P; Jiménez-Torres NV
J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
[TBL] [Abstract][Full Text] [Related]
25. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics analyses of rifampicin in adult and children populations: A systematic review.
Muda MR; Harun SN; Syed Sulaiman SA; Sheikh Ghadzi SM
Br J Clin Pharmacol; 2022 Jul; 88(7):3132-3152. PubMed ID: 35253251
[TBL] [Abstract][Full Text] [Related]
27. Intravenous infusion conditions. Implications for pharmacokinetic monitoring.
Nahata MC
Clin Pharmacokinet; 1993 Mar; 24(3):221-9. PubMed ID: 8462228
[TBL] [Abstract][Full Text] [Related]
28. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates.
Pons G; Tréluyer JM; Dimet J; Merlé Y
Ther Drug Monit; 2002 Feb; 24(1):9-14. PubMed ID: 11805715
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of intravenous rifampicin (rifampin) in neonates.
Pullen J; Stolk LM; Degraeuwe PL; van Tiel FH; Neef C; Zimmermann LJ
Ther Drug Monit; 2006 Oct; 28(5):654-61. PubMed ID: 17038881
[TBL] [Abstract][Full Text] [Related]
30. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacokinetics of rifampicin.
Acocella G
Clin Pharmacokinet; 1978; 3(2):108-27. PubMed ID: 346286
[TBL] [Abstract][Full Text] [Related]
32. Simplified dosing and monitoring of vancomycin for the burn care clinician.
Rice TL
Burns; 1992 Oct; 18(5):355-61. PubMed ID: 1445623
[TBL] [Abstract][Full Text] [Related]
33. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period.
Samardzic J; Allegaert K; Wilbaux M; Pfister M; van den Anker JN
Expert Opin Drug Metab Toxicol; 2016; 12(4):367-75. PubMed ID: 26817821
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
